Participated · Series E · Mar 2025

Supira Medical, a Shifamed portfolio company based in Los Gatos, Calif., is developing the Supira System, an investigational next-generation pVAD intended for HRPCI and cardiogenic shock. The company recently completed enrollment of its U.S. SUPPORT I Early Feasibility Study, enrolling 15 patients across four clinical sites, and reports the Supira System has benefited 85 HRPCI patients to date. The device is investigational and not approved for sale in the U.S. or elsewhere. Supira plans to expand its clinical programs for both HRPCI and cardiogenic shock, including the SUPPORT II U.S. Pivotal Study for HRPCI that will be used to seek FDA PMA approval. The company aims to use new capital to accelerate those clinical programs and further validate its low-profile, high-flow technology platform. Supira Medical is advancing the Supira System, a percutaneous ventricular assist device (pVAD) featuring a novel low-profile, high continuous-flow design intended to provide full hemodynamic support initially for high-risk percutaneous coronary interventions and subsequently for cardiogenic shock. The system is built with a 10F profile to minimize vascular complications and incorporates multiple sensors for real-time pressure measurements. The Supira System is for investigational use only and is not for sale in the U.S. or outside the U.S. Supira is led by President and CEO Dr. Nitin Salunke and is a portfolio company of Shifamed, LLC. The company plans to expand its currently enrolling OUS studies, plan for U.S. studies, and prepare for a U.S. pivotal study submission. It raised $40M in Series D financing to support those clinical and regulatory activities. Supira Medical is developing a next-generation percutaneous ventricular assist device (pVAD) intended to provide temporary mechanical circulatory support for high-risk patients. The device is aimed for use during interventional procedures such as stent placement or angioplasty and to treat patients suffering from cardiogenic shock following severe heart attacks. The company is led by CEO Dr. Nitin Salunke and is a Shifamed portfolio company based in Los Gatos, CA. Supira plans to finalize product development and initiate a first-in-human clinical study for its pVAD. Financially, the company recently completed a financing round to support those activities. Supira Medical is focused on developing a next-generation percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures. The company was formed as the newest portfolio company of Shifamed and is located in Shifamed's facility in Silicon Valley. Jean Orth was appointed CEO in December 2017 and brings more than 25 years of cardiology-centric medical device experience. Supira closed a $15.5M financing that officially closed on April 25, 2018 to support its early development efforts. The round was led by The Capital Partnership with participation from Cormorant Asset Management and Shifamed Angels. Shifamed's incubator track record includes multiple exits, providing an experienced sponsor and potential exit pathways for its portfolio companies.

Led · Series A · Dec 2023

Laza Medical is developing an AI-powered robotically-assisted imaging solution for cardiovascular interventions. The product is designed to optimize procedural workflows and elevate the standard of imaging for these procedures. The company is a Shifamed portfolio company based in Los Gatos, CA. It raised $36M in a Series A to accelerate product development and further expand the team. Laza also announced the appointment of Pablo Garcia as General Manager. Garcia previously served as Vice President of Digital Solutions for Johnson & Johnson and was the technical co-founder of Verb Surgical, a venture later acquired by Johnson & Johnson in 2020.

Led · Series B · Oct 2023

Akura Medical is a Los Gatos-based medical technology company within the Shifamed portfolio that targets venous thromboembolism (VTE) treatment. Its flagship Katana™ Thrombectomy System uses high-velocity saline jets and embedded sensors to break up diverse clot types while providing real-time pulmonary artery pressure data during procedures. Complementing the hardware, the company is building NavIQ™, a CT-based quantification platform that creates 3D pulmonary vasculature models and offers clot characterization to aid pre-procedural planning. Together, the products aim to deliver more precise, data-driven thrombectomy and improve patient outcomes. Fresh capital will accelerate product development, finalize enrollment of the QUADRA-PE clinical study, and fund key regulatory submissions. Akura also intends to establish a joint venture in Qatar to expand its commercial footprint. To date, the company remains privately held and has not disclosed revenue or user metrics.

Participated · Series B · Jun 2023

Myra Vision is developing a treatment intended to allow maximum intraocular pressure (IOP) reduction for patients with moderate to advanced glaucoma. The company is developing the Calibreye System, a novel treatment designed to allow safe outflow control to achieve maximum IOP reduction while reducing complexity and complication rates. Myra Vision is led by President and CEO Robert Chang. The company intends to use new funding to further product development, scale manufacturing capabilities, and support first-in-human investigation of the Calibreye System. It is a privately held portfolio company of Shifamed. The firm completed a $25M Series B to support these activities. Myra Vision is developing a glaucoma treatment device built around novel technology designed to allow safe outflow control to achieve maximum intraocular pressure (IOP) reduction while reducing complexity and complication rates. The company is based in Campbell, Calif., and is a Shifamed portfolio company. Led by CEO Robert Chang, Myra Vision intends to use its recent financing to advance product development, scale infrastructure, and expand its team. The company completed a $17M Series A financing and announced a name change to Myra Vision, Inc. from Myra Medical, Inc. The funding is intended to support continued development and commercialization efforts for its glaucoma treatment device. Myra Medical is a newly formed Shifamed portfolio company advancing surgical devices designed to enable maximum intraocular pressure (IOP) reduction. Its novel technology aims to safely reduce IOP while lowering the risk of hypotony, targeting improved treatment for moderate to advanced glaucoma patients. The company intends to use its recent funding to advance product development and pre-clinical programs. Myra Medical has appointed Robert Chang as Chief Executive Officer and Tracy Valorie as a strategic advisor; both bring extensive ophthalmology and medical-device experience. The company raised seed financing in 2019 to support these development plans. Shifamed, founded by serial entrepreneur Amr Salahieh, serves as the medical innovation hub backing the company.

Participated · Series C · Feb 2023

Tioga Cardiovascular develops a next-generation transseptal mitral valve replacement (TMVR) technology and is focused on mitral and tricuspid transcatheter valve solutions. The company is a privately held portfolio company of Shifamed LLC and is based in Los Gatos, Calif. Its TMVR approach emphasizes a smaller delivery system, transseptal delivery, reduced left ventricular outflow tract (LVOT) obstruction, and procedural simplicity. Tioga positions its device as a less invasive option intended to address unmet clinical needs in patients with severe mitral regurgitation. The company will use recent financing to continue product development, support pre-clinical testing, and initiate first-in-human use. Tioga highlights the large addressable market for mitral valve disease, noting it affects millions and is often undertreated due to surgical risks. Tioga Medical is a Shifamed portfolio company based in Campbell, CA that develops valve replacement solutions for mitral and tricuspid applications. Its core product is a transcatheter valve replacement technology designed to be procedurally simple and less invasive. The company is led by President and CEO Mike Dineen. Tioga raised $30M in a Series B financing led by The Capital Partnership, with participation from Cormorant Asset Management, AMED Ventures and Shifamed angel investors. The company intends to use the funds to advance product development, support pre-clinical testing and initiate clinical experience. The financing is intended to move the transcatheter valve replacement technology closer to clinical use. Tioga Medical is a Campbell, Calif.-based newly formed company developing a novel transcatheter valve replacement technology for mitral and tricuspid applications. Its core product is a less invasive, transcatheter approach intended to provide valve replacement solutions that are procedurally simple. The company’s initial focus is mitral valve disease, which the article notes is the largest structural heart valve problem and roughly four times more common than aortic stenosis. Tioga intends to use the Series A proceeds to advance its pre-clinical and clinical development programs. The company is a privately held portfolio company of Shifamed LLC and is led by President and CEO Mike Dineen. Shifamed, founded by serial entrepreneur Amr Salahieh, is described as a medical innovation hub focused on accelerating time to market, reducing risk, and increasing impact.